NUWE Stock Analysis: Buy, Sell, or Hold?
NUWE - Nuwellis, Inc. Common Stock
$3.00
0.20 (7.14%)
▲
5d:
-4.76%
30d:
+2042.86%
90d:
+150.0%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Get Alerted When NUWE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NUWE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NUWE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NUWE is currently trading at $3.00, which is considered extended relative to its 30-day fair value range of $0.02 to $2.96.
Technical Outlook: Technically, NUWE is in a downtrend. The price is approaching resistance at $0.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: NUWE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+292.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NUWE is in a downtrend. The price is approaching resistance at $0.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: NUWE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+292.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.02 -
$2.96
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.1%)
- BULLISH: Trading 292.9% below Wall St target ($11.00)
Trading Range Analysis
30-Day Trading Range
$0.02 -
$2.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.13
Resistance Level
$0.99
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.44
Wall Street Target
$11.00
(+292.9%)
Revenue Growth (YoY)
26.2%
Earnings Growth (YoY)
-99.2%
Profit Margin
-217.2%
Share & Embed Analysis
Last updated: July 14, 2026 2:12 PM ET
Data refreshes hourly during market hours. Next update: 3:12 PM
Data refreshes hourly during market hours. Next update: 3:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUWE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$74 | 64 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 62 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 50 HOLD |
